Detalles de la búsqueda
1.
Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell Therapy.
Int J Mol Sci
; 22(21)2021 Oct 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-34769156
2.
Rescue of cell cycle progression in BRAFV600E inhibitor-resistant human melanoma by a chromatin modifier.
Tumour Biol
; 39(9): 1010428317721620, 2017 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-28936920
3.
Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway.
J Immunol
; 192(8): 3981-9, 2014 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24639349
4.
Immunotherapy of Hematological Malignancies of Human B-Cell Origin with CD19 CAR T Lymphocytes.
Cells
; 13(8)2024 Apr 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38667277
5.
T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFß) signaling mediate superior tumor regression in an animal model of adoptive cell therapy.
J Transl Med
; 10: 127, 2012 Jun 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-22713761
6.
Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy.
Anticancer Drugs
; 21(9): 805-13, 2010 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20679890
7.
Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
Cancer Res
; 67(3): 1270-81, 2007 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17283164
8.
Overcoming Resistance of Human Non-Hodgkin's Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors.
Cancers (Basel)
; 10(6)2018 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-29904021
9.
Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor).
Cancers (Basel)
; 10(6)2018 May 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-29795041
10.
Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis.
Cancer Res
; 65(1): 264-76, 2005 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15665303
11.
Combination of celecoxib (Celebrex®) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas.
Am J Clin Exp Immunol
; 6(3): 27-42, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28804691
12.
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Oncogene
; 24(13): 2121-43, 2005 Mar 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-15789036
13.
Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.
Oncogene
; 24(55): 8114-27, 2005 Dec 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-16103877
14.
Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
Cancer Res
; 64(19): 7117-26, 2004 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15466208
15.
CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas.
Am J Cancer Res
; 6(2): 403-24, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27186412
16.
PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab.
Am J Cancer Res
; 6(10): 2117-2128, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27822406
17.
Raf-1 kinase inhibitor protein: structure, function, regulation of cell signaling, and pivotal role in apoptosis.
Adv Cancer Res
; 91: 169-200, 2004.
Artículo
en Inglés
| MEDLINE | ID: mdl-15327891
18.
Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis.
Mol Cancer Ther
; 3(1): 71-84, 2004 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-14749477
19.
Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis.
Mol Cancer Ther
; 2(11): 1183-93, 2003 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-14617792
20.
Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine.
Cancer Biother Radiopharm
; 17(6): 621-30, 2002 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-12537665